Market Overview

Halozyme Sees 2013 Cash Burn $45-50M, Cash Balance ~$100M

Related HALO
New Drug Could Transform Pancreatic Cancer Treatment
Halozyme Issues New Preclinical Data at ASCO: PEGPH20 Boosted T-Cell Access to Tumor Cells in Animals

Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care, today announced that the Company ended 2012 with a cash balance of approximately $100 million and expects 2013 net cash burn to be between $45 and $50 million.  The Company also announced it secured a $30 million term loan from Oxford Finance and Silicon Valley Bank.

Posted-In: News Guidance


Related Articles (HALO)

Around the Web, We're Loving...